One year after the medical device tax, as part of the Affordable Care Act went into effect, the financial impact on the medtech industry is not as bad as industry lobbyists feared, but it is still concerning to the industry. According to a recently analysis completed by MassDevice.com, the medtech industry paid at least $500 …read more.

MassDevice.com has reported that Medtronic is receiving over $1 million in repayments from a New Zealand doctor after forensics revealed the surgeon faked invoices to avoid debt. A New Zealand judge ordered surgeon Gregory Dale Finch to pay overdue invoices after ruling the doctor forged documents in order to dodge his debt. Finch attempted to …read more.

The FDA put its highest-risk Class I label on a fracture risk recall of Johnson & Johnson subsidiary DePuy Orthopaedics’ LPS LPS Lower Extremity Dovetail Intercalary Component. According to a report released today by MassDevice.com, federal healthcare regulators put their highest-risk Class I label on a recall of Johnson & Johnson subsidiary DePuy Orthopaedics’ Limb …read more.

A report just released by a coalition of medical device lobbying groups said the medical device sales tax enacted under the Affordable Care Act has already cost the orthopedics manufacturing industry $1 billion. According to the Medical Imaging & Technology Alliance and the Medical Device Manufacturers Association, the 2.3 percent medical device tax is costing …read more.

DePuy Orthopaedics has announced that the FDA granted a supplemental pre-market approval to use special software to customize its Sigma RP knee implant for individual patients physiologies. MassDevice reports the Johnson & Johnson subsidiary said the federal watchdog agency approved the use of its Trumatch Personalized Solutions system with its Sigma RP knee implant. The …read more.

Johnson & Johnson (NYSE:JNJ) is pulling the plug on its troubled metal-on-metal hip implant business, effective Aug. 31. In a statement released by JNJ subsidiary DePuy Orthopaedics, the healthcare giant said it would halt all sales of its Ultamet metal-on-metal articulation and Complete ceramic-on-metal acetabular hip system because of lower physician adoption rates and a …read more.